Legend Biotech Corporation (LEGN)
UndervaluedFundamental
45
मूल्य
$19.43
मार्केट कैप
$3.87B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19 सितंबर 2026 with claude-haiku-4-5 — shared with all users
Its BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel) is the other approved cell therapy for relapsed or refractory multiple myeloma, treating the same patients in the same transplant centres as Carvykti.
Through its Kite unit — and after buying Arcellx in April 2026 — it is bringing anito-cel, a BCMA CAR-T aimed squarely at the myeloma patients Carvykti treats, to market with a safety profile pitched at outpatient use.
Its bispecific antibody Elrexfio (elranatamab) hits the same BCMA target in the same late-line myeloma setting, and is an off-the-shelf alternative for patients who cannot wait for a CAR-T to be manufactured.
Its BCMAxCD3 bispecific Lynozyfic (linvoseltamab) competes for the same relapsed or refractory myeloma prescriptions, with a dosing schedule that thins out over time to hold patients on therapy.
बैलेंस शीट और तरलता
राजस्व
$1.27B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$-92M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$27M
कुल इक्विटी
$1.23B
कुल देनदारियाँ
$278M
Current Ratio
3.04
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$27.60
वर्तमान मूल्य
$19.43
Margin of Safety
+29.6%
Fair Value सीमा
$17.94 - $37.25
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-8.1%
P/B Ratio
3.13
P/FCF
142.26
Gross Margin
56.6%
ROIC
9.9%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
9.9%
WACC
7.4%
ROIC − WACC
+2.5 pp
ROIC पूंजी की लागत से अधिक है — कंपनी शेयरधारकों के लिए मूल्य सृजित कर रही है।
Fundamental विश्लेषण मानदंड
पास (7)
- ROIC 9.9%
- Gross Margin 56.6%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 68.8%
- Analyst Consensus 74% Buy
फेल (9)
- Price CAGR -6.81%
- P/FCF 142.26
- P/B Ratio 3.13
- CapEx intensity
- DCF valuation (Overvalued)
- ROE -8.7%
- Earnings Surprise avg -339.9%
- Net Margin Trend -28.8% vs -28.2%
- Piotroski F-Score 1/9
अनुपलब्ध (11)
- EPS data insufficient
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Carlos Santos Garcia | Chief Financial Officer | 53 |
| Ms. Ananda Elizabeth Martin Esq., J.D. | Global Compliance Officer | 51 |
| Mr. Robert Staloff | General Counsel | - |
| Dr. Ying Huang Ph.D. | Advisor | 52 |
| Dr. Yuhong Qiu Ph.D. | Interim Head of Research & Development and Senior VP of Regulatory Affairs | - |
| Mr. Birk Vanderweeen | Senior Vice President of Global Manufacturing & Supply | - |
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for LEGN, sourced from Markets Gazette.
- 6/18/2026NEGATIVEWhy Is Legend Biotech Stock Falling Thursday?
Legend Biotech Corporation (LEGN) experienced a premarket decline following the announcement of a $226 million public offering. While the offering aims to raise capital, the dilution effect of issuing new shares typically puts downward pressure on the stock price in the short term. Investors will be monitoring the use of these funds and the company's future growth prospects to assess the long-term impact of this capital raise. The immediate reaction suggests market participants are factoring in the increased share count.
via Markets Gazette